ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BJDX / news
IVF (35) ICCM (33) NXGL (28) CODX (29) ⌘ Pro Terminal →

Why BJDX Stock dropped -4.74% Today — RQD Quant Desk Flash

$0.53 -4.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.52

Bluejay Diagnostics Inc. (BJDX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BJDX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.53 (-4.74% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BJDX ranks #524 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BJDX compare to IVF and ICCM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ICCM (IceCure Medical Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BJDX?
▼

Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $19.5M in revenue (-3.0% YoY), -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.52 (-1.04%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (5)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$8 Bull$0 Base$0 Bear
📬 FREE BJDX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BJDX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY BJDX SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$0.79-13.9% Next Q
Q2 (-2Q)
43
Grade D$0.68-16.2% Next Q
Q3 (-1Q)
41
Grade D$0.57-7% Next Q
Current
38
Grade D-$0.53-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BJDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BJDX currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.80) and Max Pain ($0.56) forces dealer call-delta covering toward $7.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BJDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BJDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BJDX Stock dropped -4.74% Today — RQD Quant Desk Flash

Bluejay Diagnostics Inc. (BJDX) dropped -4.74% to $0.53, trading at 2% of its 52-week range ($0.46 – $7.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($0.46 – $7.44) with RSI-14 at 29.4 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.53 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BJDX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BJDX)

  • ✓Walkthrough of BJDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BJDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.54%▲ RESISTANCE BREAKOUT
2026-11-04O $0.56H $0.56L $0.53C $0.53VOL 197.7K
RES: $0.41SUP: $0.43SMA50: $0.80SMA200: $1.81
$7.46$5.56$3.66$1.77$-0.13RES $0.41SUP $0.43$0.532026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BJDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BJDX Butterfly Map → + Track BJDX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BJDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BJDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BJDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BJDX)

Health Care Rank #524 of 1015 ⚔️ IVF vs BJDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BJDX vs. IVF, ICCM, NXGL, CODX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bluejay Diagnostics Inc. (BJDX) ranks #524 by composite RQD confidence (38/100, grade D-) and #986 by equity capitalization ($2.4M). Within this direct 5-issuer industry benchmark cohort, BJDX leads on earnings valuation at N/A trailing P/E, while BJDX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BJDX currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BJDX ACTIVE
Bluejay Diagnostics Inc.
D- 38/100 — — -35.0% -4.74% $2.4M Benchmark Subject
IVF
INVO Fertility Inc.
D- 35/100 — 96.0% -35.0% -4.19% $2.1M /ivf-vs-bjdx →
ICCM
IceCure Medical Ltd.
E 33/100 — 36.3% -35.0% -3.14% $2.9M /iccm-vs-bjdx →
NXGL
NexGel Inc
E 28/100 — 39.5% -35.0% +7.98% $1.8M /nxgl-vs-bjdx →
CODX
Co-Diagnostics Inc.
E 29/100 — 64.3% -35.0% -3.65% $3.1M /codx-vs-bjdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001704287 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported GAAP revenue of $19.5M (-3.0% vs. FY2024 revenue of $20.1M , and -32.6% cumulative change since FY2023) , GAAP net income of -$6.8M, operating cash flow of -$6.1M, and free cash flow of -$6.2M (+23.4% YoY). On the balance sheet, BJDX closed FY2025 with $7.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $19.5M -$6.8M -$6.1M -$6.2M $7.1M —
FY2024 (FY) 2024-12-31 $20.1M -$7.7M -$7.8M -$8.1M $6.7M —
FY2023 (FY) 2023-12-31 $28.9M -$10.0M -$8.3M -$8.3M — —

3. BJDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.53 (-4.74% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BJDX ranks #524 in composite RQD confidence.

How does BJDX compare to IVF and ICCM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ICCM (IceCure Medical Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BJDX?

Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $19.5M in revenue (-3.0% YoY), -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BJDX trading relative to its 50-day, 200-day, and 52-week technical levels?

BJDX last traded at $0.53 (-4.74% on volume of 197,726 shares), positioning the stock -33.75% below its 50-day simple moving average ($0.80) and -70.72% below its 200-day simple moving average ($1.81). Across its 52-week range of $0.46 to $7.44, BJDX sits at the 1.0% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).

Direct Sub-Reports: BJDX RQD Cockpit BJDX 12M Forecast BJDX Earnings & Move BJDX Dividends & DRIP BJDX Insiders & 13F BJDX Whale Options BJDX Profit Sankey BJDX News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BJDX — Bluejay Diagnostics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bluejay Diagnostics Inc. (BJDX) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.53 (-4.74% 1D, market capitalization $2.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bluejay Diagnostics Inc. (BJDX) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. It is a Health Care issuer operating in Medical/Dental Instruments. Reported revenue in each of the three SEC financial periods is —, so the source does not show a commercial revenue stream in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported $19.5M in annual revenue (up from $20.1M in FY2024, -3.0% YoY) and -$6.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.9M revenue, -$10.0M net income) through FY2025, BJDX scaled operating cash flow to -$6.1M and free cash flow to -$6.2M, backed by $7.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.46 – $7.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlation coefficients, or second-order bottlenecks.

  • Key Question #1: Can BJDX sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$6.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BJDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BJDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bluejay Diagnostics Inc. (BJDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BJDX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BJDX Bull vs. Bear Conversation Board — What's Your Call at $0.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BJDX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BJDX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $0.68 (+21.4%)
📌 Pinned Debate

Balance sheet forensics are middling rather than distressed, with cash rising to $5.2M in FY 2025 and an Altman Z-Score of 2.5.

Balance sheet forensics are middling rather than distressed, with cash rising to $5.2M in FY 2025 and an Altman Z-Score of 2.5.. When you look under the hood at BJDX, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $7.94. My 12M target is $0.68.

SectorRotator 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.45 (-19.6%)
Spot @ $0.56

ROIC of -35% and zero FCF yield show the business is not currently converting capital into returns, with zero reported revenue across t

Here is the bear case nobody on the bull side wants to address on BJDX: ROIC of -35% and zero FCF yield show the business is not currently converting capital into returns, with zero reported revenue across three periods.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE